HOME >> BIOLOGY >> NEWS
JCI table of contents: August 1, 2007

EDITOR'S PICK: Developing a more effective vaccine for tuberculosis

The microorganism that causes tuberculosis, M. Tuberculosis, infects more than a one third of the world's population. Although the currently used vaccine (M. bovis BCG) provides young children with protection from tuberculosis, it is not effective at preventing the type of tuberculosis that most adolescents and adults suffer from. Therefore, there is an intensive research effort designed to develop new, more efficient vaccines that protect all individuals from tuberculosis.

In a study that appears in the August issue of the Journal of Clinical Investigation, Steven Porcelli and colleagues from the Albert Einstein College of Medicine, New York, show that in mice, immune cells known as CD8+ T cells are more efficiently activated by strains of M. Tuberculosis that lack a protein known as SecA2 than strains of M. Tuberculosis that express SecA2. Efficient CD8+ T cell activation was associated with increased death (by a process known as apoptosis) of another immune cell type, the macrophage. Importantly, vaccination of mice and guinea pigs with M. Tuberculosis lacking SecA2 provided increased protection against infection with M. Tuberculosis than did vaccination with M. bovis BCG. These data led the authors to suggest that this approach, in combination with others currently under development, could be used to generate a new vaccine that protects all individuals from tuberculosis.

The importance of this study for the development of new vaccines to control the tuberculosis pandemic is discussed in more detail in the accompanying commentary by W. Henry Boom from Case Western Reserve University.

TITLE: Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis

AUTHOR CONTACT:
Steven A. Porcelli
Albert Einstein College of Medicine, New York, New York, USA.
Phone: (718) 430-3228; Fax: (718) 430-8711
'"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
1-Aug-2007


Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. US Department of Defense awards $1.6 million for implantable biochip research
4. More fish oil, less vegetable oil, better for your health
5. JCI table of contents -- July 26, 2007
6. JCI table of contents: July 19, 2007
7. JCI table of contents: July 12, 2007
8. JCI table of contents: June 21, 2007
9. JCI table of contents: June 14, 2007
10. Food safety begins as vegetables grow
11. Turning the tables in chemistry

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/1/2019)... Calif. (PRWEB) , ... July 30, 2019 , ... ... Sue Behrens as the George B. and Joy Rathmann Professor in Bioprocessing and ... is an innovative leader in the life sciences industry and possesses more than ...
(Date:7/26/2019)... ... July 25, 2019 , ... Lemnis Technologies, the technology company ... include a new generation eye tracker with hassle-free calibration. The headsets will be ... 30 - August 1). SIGGRAPH attendees will be able to try Verifocal™ headsets ...
(Date:7/21/2019)... Maine (PRWEB) , ... July ... ... manufacturer Fluid Imaging Technologies ( http://www.fluidimaging.com ) announced today the release of ... FlowCam automated particle imaging and characterization platform will provide a significant increase ...
Breaking Biology News(10 mins):
(Date:8/6/2019)... ... 2019 , ... The National Science Foundation (NSF) has granted ... that will engage middle and early high school students in environmental citizen science. ... Network for Community Environmental Assessment.” Collaborative partners presenting the authentic science experiences are ...
(Date:7/23/2019)... N.J. (PRWEB) , ... July 22, 2019 , ... ... and biotech companies with best-in-class services in the fields of 3D tissue ... machine learning , Visikol initially started back in 2013 as a products ...
(Date:7/17/2019)... ... July 16, 2019 , ... ... and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for ... will have dedicated manufacturing space at the new, state-of-the-art commercial manufacturing center ...
(Date:7/9/2019)... Ky. (PRWEB) , ... July 08, 2019 , ... ... Award winner. The company’s SmartLight Indicator was recognized as the 2019 Innovative Product ... sensors industry forward. The prestigious awards were during Sensors Expo & Conference ...
Breaking Biology Technology:
Cached News: